Earswitch develops the EarMetrics platform, which places sensors in the ear canal to capture continuous vital signs and digital blood pressure measurements. The company argues the ear is a stable site proximate to central arterial signals, enabling steadier ambulatory monitoring than episodic cuff-based devices. Earswitch is targeting applications including remote patient monitoring, sleep studies and long-term condition management. Its near-term plans focus on product development, clinical validation and commercial readiness to support regulatory clearance and NHS adoption. The company is participating in an Innovate UK-funded programme to help generate clinical validation data and prepare for commercial trials. The seed funding closed will support these development and validation activities as it moves toward market readiness.

Total raised

$2M

Funding rounds

2

Latest round

Seed

Latest activity

Feb 2024